Pharming Group NV
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Pharming Group NV
Keeping Track: Pfizer And J&J’s Dueling Myeloma Bispecifics; Regeneron And Ipsen Nab Priority Vouchers
Shared REMS, diverse confirmatory trials and manufacturing delays are among the highlights in the latest US FDA drug approval news from the Pink Sheet’s US FDA Performance Tracker.
The Dutch biotech says it has made good progress globally in identifying the patients who could benefit from Joenja, its recently approved treatment for activated phosphoinositide 3-kinase delta syndrome.
Keeping Track: Pharming’s Joenja, Cidara’s Rezzayo And Incyte’s Zynyz Headline US FDA Approval Bonanza
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Pharming’s leniolisib has lost its accelerated assessment status at the European Medicines Agency while Krystal Biotech’s beremagene geperpavec will be fast-tracked once a filing has been made.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.